MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5
Post-LOEsodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride
ANDAINJECTIONINJECTABLE
Approved
Jun 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 (sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride) by Fresenius Kabi is clinical pharmacology multiple electrolytes injection, type 1, usp, ph 5. First approved in 2022.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Multiple Electrolytes Injection, Type 1, USP, pH 5.5 has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient. Multiple Electrolytes Injection, Type 1, USP, pH 5.5 produces a metabolic alkalinizing…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Fresenius Kabi
Worked on MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.